ATE466030T1 - Neues screening-verfahren - Google Patents

Neues screening-verfahren

Info

Publication number
ATE466030T1
ATE466030T1 AT03705107T AT03705107T ATE466030T1 AT E466030 T1 ATE466030 T1 AT E466030T1 AT 03705107 T AT03705107 T AT 03705107T AT 03705107 T AT03705107 T AT 03705107T AT E466030 T1 ATE466030 T1 AT E466030T1
Authority
AT
Austria
Prior art keywords
salt
screening process
new screening
eicosanoid
amino acid
Prior art date
Application number
AT03705107T
Other languages
English (en)
Inventor
Shuji Hinuma
Masaki Hosoya
Yasuaki Ito
Makoto Kobayashi
Hideyuki Tanaka
Shoichi Okubo
Ryo Fujii
Hideki Kizawa
Yuji Kawamata
Kazuhiro Ogi
Masataka Harada
Shoji Fukusumi
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE466030T1 publication Critical patent/ATE466030T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/60Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03705107T 2002-02-14 2003-02-13 Neues screening-verfahren ATE466030T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2002037131 2002-02-14
JP2002204163 2002-07-12
JP2002328696 2002-11-12
JP2003014032 2003-01-22
PCT/JP2003/001483 WO2003068959A1 (fr) 2002-02-14 2003-02-13 Nouveau procede de criblage

Publications (1)

Publication Number Publication Date
ATE466030T1 true ATE466030T1 (de) 2010-05-15

Family

ID=27739281

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03705107T ATE466030T1 (de) 2002-02-14 2003-02-13 Neues screening-verfahren

Country Status (6)

Country Link
US (1) US7214495B2 (de)
EP (1) EP1479768B1 (de)
AT (1) ATE466030T1 (de)
AU (1) AU2003211952A1 (de)
DE (1) DE60332320D1 (de)
WO (1) WO2003068959A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056685B1 (en) 2002-11-05 2006-06-06 Amgen Inc. Receptor ligands and methods of modulating receptors
CA2505322A1 (en) * 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
ATE511644T1 (de) * 2003-01-17 2011-06-15 Takeda Pharmaceutical Neues screening-verfahren
EP1659860A1 (de) * 2003-08-18 2006-05-31 Betagenon AB Neues tiermodell für typ-2-diabetes
WO2005080412A1 (en) * 2004-02-23 2005-09-01 Theratechnologies Inc Modulators of fatty acid-stimulated insulin secretion and uses thereof
CA2558585C (en) 2004-02-27 2010-10-12 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
JP4757190B2 (ja) * 2004-03-01 2011-08-24 ファルマフロンティア株式会社 血糖値の低下に供される医薬組成物
US7517910B2 (en) 2004-03-30 2009-04-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
US20060003344A1 (en) * 2004-06-30 2006-01-05 Pfizer Inc. Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
US20070122344A1 (en) * 2005-09-02 2007-05-31 University Of Rochester Medical Center Office Of Technology Transfer Intraoperative determination of nerve location
EP1929310A2 (de) * 2005-09-02 2008-06-11 Arena Pharmaceuticals, Inc. Menschlicher g-protein-gekoppelter rezeptor und modulatoren davon zur behandlung von atherosklerose und einer atherosklerosekrankheit sowie zur behandlung von leiden in verbindung mit der expression von mcp-1
EP1924546A1 (de) * 2005-09-14 2008-05-28 Amgen, Inc Konformationseingeschränkte 3- (4-hydroxy-phenyl) substitutierte propansäuren zur behandlung von stoffwechselstörungen
US8252521B2 (en) 2005-11-04 2012-08-28 Eisai R&D Management Co., Ltd. Method of screening substance useful in treating disease with the use of GPR40 and phospholipase
JP5075641B2 (ja) * 2006-01-31 2012-11-21 武田薬品工業株式会社 遺伝子改変動物およびその用途
MX2008011615A (es) * 2006-03-14 2008-09-22 Amgen Inc Derivados de acidos carboxilicos biciclicos utiles para tratar trastornos metabolicos.
US20080161744A1 (en) 2006-09-07 2008-07-03 University Of Rochester Medical Center Pre-And Intra-Operative Localization of Penile Sentinel Nodes
CA2662242C (en) * 2006-09-07 2012-06-12 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP2064193A1 (de) * 2006-09-07 2009-06-03 Amgen, Inc Heterozyklische gpr40-modulatoren
AU2008241490B2 (en) * 2007-04-16 2011-07-21 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid GPR40 modulators
EP2151236A4 (de) 2007-04-26 2013-01-16 Japan Science & Tech Agency G-protein-konjugierter rezeptoragonist
US8030354B2 (en) 2007-10-10 2011-10-04 Amgen Inc. Substituted biphenyl GPR40 modulators
US8406860B2 (en) 2008-01-25 2013-03-26 Novadaq Technologies Inc. Method for evaluating blush in myocardial tissue
WO2009111056A1 (en) * 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US10219742B2 (en) 2008-04-14 2019-03-05 Novadaq Technologies ULC Locating and analyzing perforator flaps for plastic and reconstructive surgery
EP3372250B1 (de) 2008-05-02 2019-12-25 Novadaq Technologies ULC Verfahren zur herstellung und verwendung substanzbeladener erythrozyten zur beobachtung und behandlung von mikrovaskulärer hämodynamik
AU2009303475B2 (en) * 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
US10492671B2 (en) 2009-05-08 2019-12-03 Novadaq Technologies ULC Near infra red fluorescence imaging for visualization of blood vessels during endoscopic harvest
JP6028096B2 (ja) 2012-06-21 2016-11-16 ノバダック テクノロジーズ インコーポレイテッド 血管造影及びかん流の定量化並びに解析手法
CN107209118B (zh) 2014-09-29 2021-05-28 史赛克欧洲运营有限公司 在自体荧光存在下生物材料中目标荧光团的成像
EP3203902B1 (de) 2014-10-09 2021-07-07 Novadaq Technologies ULC Quantifizierung des absoluten blutströmung in gewebe mittels fluoreszenzvermittelter photoplethysmographie
CA3049922A1 (en) 2017-02-10 2018-08-16 Novadaq Technologies ULC Open-field handheld fluorescence imaging systems and methods

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555339B1 (en) 1997-04-14 2003-04-29 Arena Pharmaceuticals, Inc. Non-endogenous, constitutively activated human protein-coupled receptors
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides
US7241579B2 (en) * 2000-12-22 2007-07-10 Smithkline Beecham Corporation Method of screening for GPR40 ligands
GB0031527D0 (en) * 2000-12-22 2001-02-07 Smithkline Beecham Plc New use

Also Published As

Publication number Publication date
WO2003068959A1 (fr) 2003-08-21
EP1479768B1 (de) 2010-04-28
DE60332320D1 (de) 2010-06-10
EP1479768A1 (de) 2004-11-24
US7214495B2 (en) 2007-05-08
AU2003211952A1 (en) 2003-09-04
EP1479768A4 (de) 2006-02-01
US20050089866A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
ATE466030T1 (de) Neues screening-verfahren
ATE490323T1 (de) Adiponektin-rezeptor und dafür kodierendes gen
DE60224536D1 (de) Verfahren zur herstellung von l-aminosäuren unter verwendung von stämmen aus der familie der enterobacteriaceae
ATE536406T1 (de) Neuartiger zytokin-zcytor17-ligand
IN2014CN02050A (de)
SE9704836D0 (sv) Novel receptor
DE602005009856D1 (de) Verfahren zur reinigung von fsh
ATE511644T1 (de) Neues screening-verfahren
NO20031033L (no) Reseptor i EDb-fibronectindomene
WO2003021262A1 (fr) Procede de criblage
ATE494550T1 (de) Neues screening-verfahren
WO2003082320A1 (fr) Nouveau procede de criblage
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του
ATE445159T1 (de) Neues screening-verfahren
EP1559721A4 (de) Neue fprl1-liganden und deren verwendung
DE602004016006D1 (de) Screening-verfahren
ATE405579T1 (de) Zwei gonadotropin-freisetzende hormone und methode zur isolierung
WO2003021263A1 (fr) Utilisation d'une proteine de recepteur couple a une proteine g
EP1467207A4 (de) Screening-verfahren
SE9902763D0 (sv) Novel receptor
WO2002061074A1 (fr) Nouvelle proteine et adn la comprenant
DE50312447D1 (de) Verfahren zur herstellung von 4,6-dichlor-5-fluorpyrimidin
WO2002029053A1 (fr) Nouvelle proteine de recepteur couple a la proteine g et adn correspondant

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties